IP Library Granted Patent US 9,550,823
Granted Patent B2
US 9,550,823 · App. 14/963,178 · Granted Jan 24, 2017

Fucosylation-deficient cells

Inventors: Gang Chen (Yorktown Heights, NY); Darya Burakov (Yonkers, NY); James P. Fandl (LaGrangeville, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
C07K16/00C07K16/2863C07K16/2866C12N9/0006C12N15/00C12P21/005C07K2317/14C07K2317/41Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,550,823
App. No.
14/963,178
Granted
Jan 24, 2017
Kind
B2
Abstract

An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

Claims (15)

1. A method for making a glycoprotein with reduced fucosylation, comprising:

culturing a mammalian cell that expresses a GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase (FX) protein comprising the amino acid sequence of SEQ ID NO: 1, except for an amino acid substitution of L289S, at a temperature of about 37° C. and in the absence of an external fucose source, wherein the cell expresses a glycoprotein; and, isolating the glycoprotein from the culture.

2. A method for making a glycoprotein with reduced fucosylation, comprising:

culturing a mammalian cell that expresses a FX protein that comprises the amino acid sequence of SEQ ID NO: 1, except for a first amino acid substitution of L289S and a second amino acid substitution selected from the group consisting of N79S, N90K, P136L, and G211R, at a temperature of about 37° C. and in the absence of an external fucose source, wherein the cell expresses a glycoprotein; and, isolating the glycoprotein from the culture.

3. The method of claim 1 , wherein said glycoprotein comprises an immunoglobulin CH2 region and an immunoglobulin CH3 region.

4. The method of claim 3 , wherein the glycoprotein is an antibody.

5. The method of claim 1 , wherein said cell is a Chinese hamster ovary (CHO) cell.

6. The method of claim 1 , wherein no more than 6% of said glycoprotein is fucosylated when said cell is cultured at a temperature of about 37° C.

7. The method of claim 1 , wherein no more than 2% of said glycoprotein is fucosylated when said cell is cultured at a temperature of about 37° C.

8. The method of claim 2 , wherein said second amino acid substitution is N90K.

9. The method of claim 8 , wherein said glycoprotein comprises an immunoglobulin CH2 region and an immunoglobulin CH3 region.

10. The method of claim 9 , wherein the glycoprotein is an antibody.

11. The method of claim 8 , wherein said cell is a Chinese hamster ovary (CHO) cell.

12. The method of claim 8 , wherein no more than 6% of said glycoprotein is fucosylated when said cell is cultured at a temperature of about 37° C.

13. The method of claim 8 , wherein no more than 2% of said glycoprotein is fucosylated when said cell is cultured at a temperature of about 37° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2016
From: CHEN, GANG; BURAKOV, DARYA; FANDL, JAMES P.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 037923/0027 →
Continuity (5)
Division 13779952 · Feb 28, 2013
Division 12791637 · Jun 1, 2010
Provisional Application 61348858 · May 27, 2010
Provisional Application 61183400 · Jun 2, 2009
Related Publication 20160090410A1 · Mar 31, 2016